GlassScriptPhysician profile
Ting Fang Suarez
NPI 1124021498
$156,055.99
in general payments reported to CMS, 2019-2025
15 companies · $41K in 2025
The $41K reported for 2025 was more than what 96% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $285 · 2022: $23K · 2023: $58K · 2024: $33K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $128K · Food and Beverage: $4,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $128,013.11 |
| Food and Beverage | $4,061.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| National Marrow Donor Program | $154,619.11 | 2022-2025 | |
| Allergan, INC. | $380.82 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $245.06 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $193.04 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $124.15 | 2019 | |
| Sun Pharmaceutical Industries INC. | $123.16 | 2019-2020 | |
| Genentech USA, INC. | $113.68 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $60.12 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $41.43 | 2019-2020 | |
| Shire North American Group INC | $33.49 | 2019 | |
| Abbvie INC. | $32.16 | 2022 | |
| Eyevance Pharmaceuticals LLC | $30.18 | 2019 | |
| Ocular Therapeutix, INC. | $23.65 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.99 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.95 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ting Fang Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.